{
  "_originalData": {
    "identity": {
      "bacteriumName": "Burkholderia pseudomallei",
      "aliases": [
        "Melioidosis"
      ],
      "lastUpdated": "2025-04-22",
      "clsiCategory": "Other Non-Enterobacterales",
      "classification": {
        "gramStain": "Gram-negative",
        "morphology": "Bacilli",
        "respiration": "Aerobic",
        "notes": []
      },
      "strainDetails": [],
      "biochemicalTests": "Gram-negative rod, oxidase +, motile, catalase +, non-lactose fermenter, arginine dihydrolase +, resistant to gentamicin and colistin."
    },
    "clinicalProfile": {
      "summary": "Burkholderia pseudomallei causes melioidosis, a serious infection with diverse manifestations including pneumonia, skin and deep tissue abscesses, bacteremia, and bone, joint, or CNS infections. It is a major cause of fatal pneumonia and sepsis in endemic regions.",
      "pathophysiologyPearls": [
        "Infection is acquired through percutaneous inoculation, inhalation, or ingestion from contaminated soil or water.",
        "The bacterium can remain latent for years before reactivation."
      ],
      "keySignsAndSymptoms": [
        "Fever",
        "Cough, chest pain (pneumonia)",
        "Localized pain, swelling, ulceration (skin/soft tissue)",
        "Focal neurological deficits (CNS infection)",
        "Bone or joint pain"
      ],
      "clinicalSyndromes": [
        {
          "syndromeName": "Pneumonia",
          "description": "The most common presentation of melioidosis."
        },
        {
          "syndromeName": "Skin and Soft Tissue Infection",
          "description": "Can present as cellulitis or abscesses."
        },
        {
          "syndromeName": "Bacteremia",
          "description": "Can occur with or without a clear focus of infection."
        },
        {
          "syndromeName": "Bone and Joint Infection",
          "description": "Septic arthritis and osteomyelitis can occur."
        },
        {
          "syndromeName": "Central Nervous System (CNS) Infection",
          "description": "Can manifest as brain abscesses or meningoencephalitis."
        },
        {
          "syndromeName": "Deep Tissue Abscess",
          "description": "Abscesses can form in various organs, such as the liver, spleen, or prostate."
        }
      ],
      "stagesOfIllness": [],
      "highRiskPopulations": [
        "Individuals in endemic areas (Southeast Asia, northern Australia)",
        "Travelers to endemic areas",
        "Patients with diabetes, chronic kidney disease, or alcohol use disorder"
      ],
      "transmissionVectors": [
        "Contaminated soil and water"
      ],
      "prognosisNotes": [
        "Relapse is a concern, necessitating long-term eradication therapy."
      ]
    },
    "resistanceProfile": {
      "groupIntrinsicResistance": [],
      "intrinsicResistance": [
        {
          "drugOrClass": "Gentamicin",
          "notes": ""
        },
        {
          "drugOrClass": "Colistin",
          "notes": ""
        }
      ],
      "majorMechanisms": [],
      "clinicalAlerts": [
        {
          "alertTitle": "Bioterrorism Agent",
          "details": "Burkholderia pseudomallei is considered a potential agent of bioterrorism."
        }
      ]
    },
    "treatment": {
      "generalNotes": [
        "Treatment consists of an initial intravenous (IV) phase followed by a prolonged oral eradication phase to prevent relapse."
      ],
      "drugsToAvoid": [],
      "adjunctiveTherapies": [],
      "regimens": [
        {
          "context": {
            "type": "Directed",
            "condition": "Melioidosis",
            "patientPopulation": [
              "Adults",
              "Children"
            ],
            "isolateSource": "Various"
          },
          "recommendations": [
            {
              "preference": "Primary",
              "strategy": "Sequential",
              "steps": [
                {
                  "step": 1,
                  "duration": "See Antimicrobial Stewardship section",
                  "drugs": [
                    {
                      "drugName": "Ceftazidime",
                      "dose": "2 gm (child 50 mg/kg)",
                      "route": "IV",
                      "frequency": "q6h",
                      "comments": ""
                    },
                    {
                      "drugName": "Meropenem",
                      "dose": "1 gm (child 25 mg/kg)",
                      "route": "IV",
                      "frequency": "q8h",
                      "comments": "Preferred for CNS disease at double the dose."
                    }
                  ]
                },
                {
                  "step": 2,
                  "duration": "At least 3 months",
                  "drugs": [
                    {
                      "drugName": "TMP-SMX",
                      "dose": "6-8 mg/kg",
                      "route": "PO",
                      "frequency": "BID",
                      "comments": "Dosed based on TMP component."
                    }
                  ]
                }
              ],
              "notes": [
                "Eradication therapy is initiated following initial IV therapy to prevent relapse."
              ]
            },
            {
              "preference": "Alternative",
              "strategy": "Sequential",
              "steps": [
                {
                  "step": 2,
                  "duration": "At least 3 months",
                  "drugs": [
                    {
                      "drugName": "Doxycycline",
                      "dose": "100",
                      "route": "PO",
                      "frequency": "BID",
                      "comments": "Less effective than TMP-SMX."
                    },
                    {
                      "drugName": "Amoxicillin-clavulanate",
                      "dose": "20 mg/5 mg/kg",
                      "route": "PO",
                      "frequency": "TID",
                      "comments": "Less effective than TMP-SMX. Dose may be poorly tolerated due to GI intolerance."
                    }
                  ]
                }
              ],
              "notes": [
                "Alternative eradication therapies are considered less effective than TMP-SMX."
              ]
            }
          ]
        }
      ]
    },
    "laboratoryProfile": {
      "testingIndications": [
        "Culture from blood, sputum, wound, or other relevant sites is essential for diagnosis."
      ],
      "methodologyNotes": [
        "Laboratory staff should be alerted to the possibility of B. pseudomallei as it is a BSL-3 pathogen."
      ],
      "recommendedPanel": [],
      "specialTests": [],
      "reportingRules": [],
      "antimicrobialBreakpoints": []
    },
    "additionalInformation": {
      "diagnosticNotes": {
        "summary": "",
        "biosafetyWarning": "Burkholderia pseudomallei is a BSL-3 pathogen. Laboratory personnel should be notified of suspected cases to ensure appropriate safety precautions are taken.",
        "methods": []
      },
      "preventionAndScreening": [],
      "treatmentLifecycle": [],
      "antimicrobialStewardship": [
        "In an open-label randomized controlled trial, TMP-SMX for 12 weeks was non-inferior to 20 weeks for total mortality and a composite of mortality and disease recurrence.",
        "Duration of IV therapy depends on the site and severity of infection: Septic joint, deep tissue abscess: 4 weeks; Osteomyelitis: 6 weeks; CNS infection: 8 weeks.",
        "Darwin Melioidosis Treatment Guideline suggests a minimum of 3 weeks of IV antibiotic if bacteremic plus single lobe infiltrate or multi-lobe pneumonia without bacteremia, and a minimum of 4 weeks if bacteremic with multi-lobe pneumonia."
      ],
      "drugSpecificPearls": [],
      "guidelineReferences": [
        {
          "source": "PLoS Neglected Tropical Diseases",
          "citation": "PLoS Negl Trop Dis. 2023; 17:e0011382",
          "summaryOrNote": "Meta-analysis comparing various treatment regimens."
        },
        {
          "source": "Australian Journal of General Practice",
          "citation": "Aust J Gen Pract. 2019; 48:327-332",
          "summaryOrNote": "Review of melioidosis."
        },
        {
          "source": "Clinical Microbiology Reviews",
          "citation": "Clin Microbiol Rev. 2020;33:e00006",
          "summaryOrNote": "Review of melioidosis."
        },
        {
          "source": "Current Opinion in Infectious Diseases",
          "citation": "Curr Opin Infect Dis. 2022; 35:517",
          "summaryOrNote": "Review of melioidosis."
        },
        {
          "source": "New England Journal of Medicine",
          "citation": "N Engl J Med 2022;386:861",
          "summaryOrNote": "Report on a US outbreak associated with imported aromatherapy spray."
        },
        {
          "source": "PLoS Neglected Tropical Diseases",
          "citation": "PLoS Negl Trop Dis. 2020; 14:e0008659",
          "summaryOrNote": "Darwin Melioidosis Treatment Guideline."
        },
        {
          "source": "Clinical Infectious Diseases",
          "citation": "Clin Infect Dis. 2021; 73:e3627",
          "summaryOrNote": "Trial comparing 12 vs 20 weeks of TMP-SMX eradication therapy."
        }
      ]
    }
  },
  "_metadata": {
    "originalKeys": [
      "identity",
      "clinicalProfile",
      "resistanceProfile",
      "treatment",
      "laboratoryProfile",
      "additionalInformation"
    ],
    "conversionTimestamp": "2025-07-15T03:16:49.324Z",
    "sourceFormat": "modern"
  },
  "identity": {
    "bacteriumName": {
      "sources": [
        "identity.bacteriumName"
      ],
      "value": "Burkholderia pseudomallei"
    },
    "aliases": {
      "sources": [
        "identity.aliases"
      ],
      "value": [
        "Melioidosis"
      ]
    },
    "lastUpdated": {
      "sources": [
        "identity.lastUpdated"
      ],
      "value": "2025-04-22"
    },
    "classification": {
      "sources": [
        "identity.classification"
      ],
      "value": {
        "gramStain": "Gram-negative",
        "morphology": "Bacilli",
        "respiration": "Aerobic",
        "notes": []
      }
    }
  },
  "clinicalInformation": {
    "sources": [
      "clinicalProfile"
    ],
    "value": {
      "summary": "Burkholderia pseudomallei causes melioidosis, a serious infection with diverse manifestations including pneumonia, skin and deep tissue abscesses, bacteremia, and bone, joint, or CNS infections. It is a major cause of fatal pneumonia and sepsis in endemic regions.",
      "pathophysiologyPearls": [
        "Infection is acquired through percutaneous inoculation, inhalation, or ingestion from contaminated soil or water.",
        "The bacterium can remain latent for years before reactivation."
      ],
      "keySignsAndSymptoms": [
        "Fever",
        "Cough, chest pain (pneumonia)",
        "Localized pain, swelling, ulceration (skin/soft tissue)",
        "Focal neurological deficits (CNS infection)",
        "Bone or joint pain"
      ],
      "clinicalSyndromes": [
        {
          "syndromeName": "Pneumonia",
          "description": "The most common presentation of melioidosis."
        },
        {
          "syndromeName": "Skin and Soft Tissue Infection",
          "description": "Can present as cellulitis or abscesses."
        },
        {
          "syndromeName": "Bacteremia",
          "description": "Can occur with or without a clear focus of infection."
        },
        {
          "syndromeName": "Bone and Joint Infection",
          "description": "Septic arthritis and osteomyelitis can occur."
        },
        {
          "syndromeName": "Central Nervous System (CNS) Infection",
          "description": "Can manifest as brain abscesses or meningoencephalitis."
        },
        {
          "syndromeName": "Deep Tissue Abscess",
          "description": "Abscesses can form in various organs, such as the liver, spleen, or prostate."
        }
      ],
      "stagesOfIllness": [],
      "highRiskPopulations": [
        "Individuals in endemic areas (Southeast Asia, northern Australia)",
        "Travelers to endemic areas",
        "Patients with diabetes, chronic kidney disease, or alcohol use disorder"
      ],
      "transmissionVectors": [
        "Contaminated soil and water"
      ],
      "prognosisNotes": [
        "Relapse is a concern, necessitating long-term eradication therapy."
      ]
    }
  },
  "resistanceInformation": {
    "sources": [
      "resistanceProfile"
    ],
    "value": {
      "groupIntrinsicResistance": [],
      "intrinsicResistance": [
        {
          "drugOrClass": "Gentamicin",
          "notes": ""
        },
        {
          "drugOrClass": "Colistin",
          "notes": ""
        }
      ],
      "majorMechanisms": [],
      "clinicalAlerts": [
        {
          "alertTitle": "Bioterrorism Agent",
          "details": "Burkholderia pseudomallei is considered a potential agent of bioterrorism."
        }
      ]
    }
  },
  "treatmentData": {
    "treatmentData": {
      "_treatmentMetadata": {
        "originalFormat": "modern"
      },
      "standardizedRegimens": [
        {
          "regimenId": "modern-0-0-0",
          "extractedFrom": "treatment.regimens[0].recommendations[0].steps[0]",
          "context": {
            "type": "directed",
            "condition": "Melioidosis",
            "severity": "unknown",
            "patientFactors": {
              "population": [
                "Adults",
                "Children"
              ],
              "labFindings": "Various"
            }
          },
          "preference": "primary",
          "drugs": [
            {
              "drugName": "Ceftazidime",
              "dose": "2 gm (child 50 mg/kg)",
              "route": "IV",
              "frequency": "q6h",
              "duration": "See Antimicrobial Stewardship section",
              "comments": "",
              "originalText": "Ceftazidime 2 gm (child 50 mg/kg) IV q6h"
            },
            {
              "drugName": "Meropenem",
              "dose": "1 gm (child 25 mg/kg)",
              "route": "IV",
              "frequency": "q8h",
              "duration": "See Antimicrobial Stewardship section",
              "comments": "Preferred for CNS disease at double the dose.",
              "originalText": "Meropenem 1 gm (child 25 mg/kg) IV q8h"
            }
          ]
        },
        {
          "regimenId": "modern-0-0-1",
          "extractedFrom": "treatment.regimens[0].recommendations[0].steps[1]",
          "context": {
            "type": "directed",
            "condition": "Melioidosis",
            "severity": "unknown",
            "patientFactors": {
              "population": [
                "Adults",
                "Children"
              ],
              "labFindings": "Various"
            }
          },
          "preference": "primary",
          "drugs": [
            {
              "drugName": "TMP-SMX",
              "dose": "6-8 mg/kg",
              "route": "PO",
              "frequency": "BID",
              "duration": "At least 3 months",
              "comments": "Dosed based on TMP component.",
              "originalText": "TMP-SMX 6-8 mg/kg PO BID"
            }
          ]
        },
        {
          "regimenId": "modern-0-1-0",
          "extractedFrom": "treatment.regimens[0].recommendations[1].steps[0]",
          "context": {
            "type": "directed",
            "condition": "Melioidosis",
            "severity": "unknown",
            "patientFactors": {
              "population": [
                "Adults",
                "Children"
              ],
              "labFindings": "Various"
            }
          },
          "preference": "alternative",
          "drugs": [
            {
              "drugName": "Doxycycline",
              "dose": "100",
              "route": "PO",
              "frequency": "BID",
              "duration": "At least 3 months",
              "comments": "Less effective than TMP-SMX.",
              "originalText": "Doxycycline 100 PO BID"
            },
            {
              "drugName": "Amoxicillin-clavulanate",
              "dose": "20 mg/5 mg/kg",
              "route": "PO",
              "frequency": "TID",
              "duration": "At least 3 months",
              "comments": "Less effective than TMP-SMX. Dose may be poorly tolerated due to GI intolerance.",
              "originalText": "Amoxicillin-clavulanate 20 mg/5 mg/kg PO TID"
            }
          ]
        }
      ]
    }
  },
  "laboratoryData": {
    "sources": [
      "laboratoryProfile"
    ],
    "value": {
      "testingIndications": [
        "Culture from blood, sputum, wound, or other relevant sites is essential for diagnosis."
      ],
      "methodologyNotes": [
        "Laboratory staff should be alerted to the possibility of B. pseudomallei as it is a BSL-3 pathogen."
      ],
      "recommendedPanel": [],
      "specialTests": [],
      "reportingRules": [],
      "antimicrobialBreakpoints": []
    }
  },
  "additionalData": {
    "antimicrobialStewardship": {
      "sources": [
        "antimicrobial_stewardship",
        "antimicrobialStewardship"
      ],
      "value": []
    },
    "comments": {
      "preservedStructure": {
        "originalFormat": "object"
      }
    },
    "diagnosis": {
      "sources": [
        "diagnosis"
      ],
      "value": []
    },
    "allOtherKeys": {}
  }
}